ABCELLERA BIOLOGICS INC (ABCL)

CA00288U1066 - Common Stock

4.53  +0.04 (+0.89%)

After market: 4.6081 +0.08 (+1.72%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ABCL. ABCL was compared to 58 industry peers in the Life Sciences Tools & Services industry. While ABCL has a great health rating, there are worries on its profitability. ABCL is valied quite expensively at the moment, while it does show a decent growth rate.



1

1. Profitability

1.1 Basic Checks

In the past year ABCL has reported negative net income.
ABCL had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ABCL reported negative net income in multiple years.
Of the past 5 years ABCL 4 years had a positive operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -9.83%, ABCL is in line with its industry, outperforming 44.83% of the companies in the same industry.
ABCL has a Return On Equity (-12.70%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -9.83%
ROE -12.7%
ROIC N/A
ROA(3y)4.03%
ROA(5y)2.91%
ROE(3y)5.04%
ROE(5y)1.61%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABCL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABCL has been increased compared to 1 year ago.
ABCL has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ABCL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ABCL has an Altman-Z score of 2.74. This is not the best score and indicates that ABCL is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.74, ABCL perfoms like the industry average, outperforming 51.72% of the companies in the same industry.
ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.74
ROIC/WACCN/A
WACC10.98%

2.3 Liquidity

ABCL has a Current Ratio of 7.33. This indicates that ABCL is financially healthy and has no problem in meeting its short term obligations.
ABCL has a better Current ratio (7.33) than 86.21% of its industry peers.
A Quick Ratio of 7.32 indicates that ABCL has no problem at all paying its short term obligations.
ABCL has a Quick ratio of 7.32. This is amongst the best in the industry. ABCL outperforms 86.21% of its industry peers.
Industry RankSector Rank
Current Ratio 7.33
Quick Ratio 7.32

5

3. Growth

3.1 Past

ABCL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -204.00%.
The Revenue for ABCL has decreased by -92.16% in the past year. This is quite bad
ABCL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 34.00% yearly.
EPS 1Y (TTM)-204%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-70%
Revenue 1Y (TTM)-92.16%
Revenue growth 3Y-45.37%
Revenue growth 5Y34%
Revenue growth Q2Q-57.31%

3.2 Future

ABCL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.83% yearly.
Based on estimates for the next years, ABCL will show a very strong growth in Revenue. The Revenue will grow by 36.24% on average per year.
EPS Next Y-15.73%
EPS Next 2Y-9.51%
EPS Next 3Y-12.97%
EPS Next 5Y16.83%
Revenue Next Year25.45%
Revenue Next 2Y33.96%
Revenue Next 3Y28.75%
Revenue Next 5Y36.24%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

0

4. Valuation

4.1 Price/Earnings Ratio

ABCL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABCL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

ABCL's earnings are expected to decrease with -12.97% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.51%
EPS Next 3Y-12.97%

0

5. Dividend

5.1 Amount

ABCL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (3/28/2024, 8:00:00 PM)

After market: 4.6081 +0.08 (+1.72%)

4.53

+0.04 (+0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.33B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -9.83%
ROE -12.7%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 7.33
Quick Ratio 7.32
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-204%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-15.73%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-92.16%
Revenue growth 3Y-45.37%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y